PROGRESS OF LIPOSOMES AS ANTIBIOTIC CARRIERS_Chinese Journal of Reparative and Reconstructive Surgery

Authors：

YANG Duming ^1,2 , XU Yongqing ¹ , LI Fubing ¹ , LIU hua ¹

1Department of Orthopaedics, Kunming General Hospital of Chengdu Military Command, the Orthopaedic Trauma Institute of Chinese PLA, Kunming Yunnan, 650032, P.R.China;;
2Department of Graduate Education, Kuming Medical Univeristy. Corresponding author: XU Yongqing, E-mail: xuyongqingkm@163.net;

Corresponding author：

Keywords：

Liposome; Antibiotic carrier; Research progress

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To reviewe the research progress of liposomes as antibiotic carriers. Methods Domestic and abroad literature concerning liposomes as antibiotic carriers was reviewed and analyzed thoroughly. Results Liposomes as antibiotic carriers can significantly improve drug distribution, enhance antibacterial activity, and reduce the side effects of antibiotics during treatment. But it also has some problems, such as poor physical and chemical stabilities and low encapsulation efficiency. Conclusion Liposomes as antibiotic carriers can reduce the drug toxicity, improve drug biodistribution, and pharmacokinetics, and bring the dawn to completely curing infections disease.

Citation： YANG Duming,XU Yongqing,LI Fubing,LIU hua. PROGRESS OF LIPOSOMES AS ANTIBIOTIC CARRIERS. Chinese Journal of Reparative and Reconstructive Surgery, 2012, 26(11): 1387-1390. doi: Copy

1.	Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipid. J Mol Boil, 1965, 13(1): 238-252.
2.	Gregoriadis G, Wills EJ, Swain CP, et al. Drug-carrier potential of liposomes in cancer chemotherapy. Lancet, 1974, 1(7870): 1313-1316.
3.	陆彬. 药剂学. 北京: 中国医药科技出版社, 2003: 454.
4.	Drulis-Kawa Z, Dorotkiewicz-Jach A. Liposomes as delivery systems for antibiotics. Int J Pharm, 2010, 387(1-2): 187-198.
5.	Shen Y, Ji Y, Xu S, et al. Multivesicular liposome formulations for the sustained delivery of ropivacaine hydrochloride: preparation, characterization, and pharmacokinetics. Drug Deliv, 2011, 18(5): 361-366.
6.	Cao J, Sun J, Wang X, et al. N-trimethyl chitosan-coated multivesicular liposomes for oxymatrine oral delivery. Drug Dev Ind Pharm, 2009, 35(11): 1339-1347.
7.	Akiyama M. Slow change in the repeat period of multilamellar dimyristoyl phosphatidylcholine accompanied by thermal phase transition. Biochim Biophys Acta, 1981, 644(1): 89-95.
8.	Bakker-Woudenberg IA. Long-circulating sterically stabilized liposomes as carriers of agents for treatment or for imaging ionfectious foci. Int J Antimicrob Agents, 2002, 19(4): 299-311.
9.	Abeylath SC, Turos E. Drug delivery approaches to overcome bacterial resistence to beta-lactam antibiotics. Expert Opin Drug Deliv, 2008, 5(9): 931-949.
10.	Jia Y, Joly H, Omri A. Liposomes as a carrier for gentamicin delivery: development and evaluation of the physicochemical properties. Int J Pharm, 2008, 359(1-2): 254-263.
11.	Hamidi M, Azadi A, Rafiei P. Pharmacokinetic consequences of pegylattion. Drug Delive, 2006, 13(6): 399-409.
12.	Schiffelers R, Storm G, Bakker-Woudenberg I. Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies. J Antimicrob Chemother, 2001, 48(3): 333-344.
13.	Bakker-Woudenberg IA, Schiffelers RM, Storm G, et al. Long-circulating sterically stabilized liposomes in the treatment of infections. Methods Enzymol, 2005, 391: 228-260.
14.	Beaulac C, Clement-Major S, Hawari J, et al. In vitro kinetics of drug release and pulmonary retention of microencapsulated antibiotic in liposomal formulations in relation to the lipid composition. J Microencapsul, 1997, 14(3): 335-348.
15.	Ceh B, Winterhalter M, Frederik PM, et al. Stealth liposomes: from theory to product. Adv Drug Deliv Rev, 1997, 24(2): 165-177.
16.	Bakker-Woudenberg IA, ten Kate MT, Guo L, et al. Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection. Antimicrob Agents Chemother, 2002, 46(8): 2575-2581.
17.	Bakker-Woudenberg IA, ten Kate MT, Guo L, et al. Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats. Antimicrob Agents Chemother, 2011, 45(5): 1487-1492.
18.	Muppidi K, Wang J, Betageri G, et al. PEGylated liposome encapsulation increases the lung tissue concentration of vancomycin. Antimicrob Agents Chemother, 2011, 55(10): 4537-4542.
19.	Tomioka H, Saito H, Sato K, et al. Therapeutic efficacy of liposome-encapsulated kanamycin against Mycobacterium intracellulare infection induced in mice. Am Rev Respir Dis, 1991, 144(3 Pt 1): 575-579.
20.	Bakker-Woudenberg IA, Lokerse AF, Vink-van den Berg JC, et al. Liposome-encapsulated ampicillin against Listeria monocytogenes in vivo and in vitro. Infection, 1988, 16 Suppl 2: S165-170.
21.	Düzgüneş N, Perumal VK, Kesavalu L, et al. Enhanced effect of liposome-encapsulated amikacin on Mycobacterium avium-M. intracellulare complex infection in beige mice. Antimicrob Agents Chemother, 1988, 32(9): 1404-1411.
22.	Anderson JC, Kirby CJ. The effect of incorporation of cloxacillin in liposomes on treatment of experimental staphylococcal mastitis in mice. J Vet Pharmacol Ther, 1986, 9(3): 303-309.
23.	Bakker-Woudenberg IA, Lokerse AF, Vink-van den Berg JC, et al. Effect of liposome-entrapped ampicillin on survival of Listeria monocytogenes in murine peritoneal macrophages. Antimicrob Agents Chemother, 1986, 30(2): 295-300.
24.	Salem II, Düzgüneş N. Efficacies of cyclodextrin-complexed and liposome-encapsulated clarithromycin against Mycobacterium avium complex infection in human macrophages. Int J Pharm, 2003, 250(2): 403-414.
25.	Onyeji CO, Nightingale CH, Tessier PR, et al. Activities of clarithromycin, azithromycin, and ofloxacin in combination with liposomal or unencapsulated granulocyte-macrophage colony-stimulating factor against intramacrophage Mycobacterium avium-Mycobacterium intracellulare. J Infect Dis, 1995, 172(3): 810-816.
26.	Sou K, Goins B, Oyajobi BO, et al. Bone marrow-targeted liposomal carriers. Expert Opin Drug Deliv, 2011, 8(3): 317-328.
27.	Sutherland IW. The biofilm matrix—an immobilised but dynamic environment. Trends Microbiol, 2001, 9(5): 222-227.
28.	Kim JH, Gias M, Jones MN. The adsorption of cationic liposomes to Staphylococcus aureus biofilms. Colloids Surf A Physicochem Eng Asp, 1999, 149(1): 561-570．.
29.	Tollemar J, Duraj F, Ericzon BG. Liposomal amphotericin B treatment in a 9-month-old liver recipient. Mycoses, 1990, 33(5): 251-252.
30.	Katz NM, Pierce PF, Anzeck RA, et al. Liposomal amphotericin B for treatment of pulmonary aspergillosis in a heart transplant patient. J Heart Transplant, 1990, 9(1): 14-17.
31.	Halwani M, Yebio B, Suntres ZE, et al. Co-encapsulation of gallium with gentamicin in liposomes enhances antimicrobial activity of gentamicin against Pseudomonas aeruginosa. J Antimicrob Chemother, 2008, 62(6): 1291-1297.
32.	Offner F, Krcmery V, Boogaerts M, et al. Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B. Antimicrob Agents Chemother, 2004, 48(12): 4808-4812.
33.	Abdel-Rhaman MS, Soliman W, Habib F, et al. A New long-acting liposomal topical antifungal formula: human clinical study. Cornea, 2012, 31(2): 126-129.
34.	Okusanya OO, Bhavnani SM, Hammel J, et al. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob Agents Chemother, 2009, 53(9): 3847-3854.
35.	殷凯生, 王彤, 廖万清, 等. 国产注射用两性霉素B脂质体治疗深部真菌病的疗效与安全性的临床研究. 中华医学感染学杂志, 2004, 14(8): 850-854.
36.	Sharma A, Sharma US. Liposomes in drug delivery: progress and limitations. Int J Pharm, 1997, 154(2): 123-140.
37.	Mouritsen OG, Jørgensen K. A new look at lipid-membrane structure in relation to drug research. Pharm Res, 1998, 15(10): 1507-1519.
38.	Gubernator J, Drulis-Kawa Z, Dorotkiewicz-Jach A, et al. In vitro antimicrobial activity of liposomes containing ciprofloxacin, meropenem and gentamicin against Gram-negative clinical bacterial strains. Lett Drug Des Discov, 2007, 4(4): 297-304.
39.	Ulrich AS. Biophysical aspects of using liposomes as delivery vehicles. Biosci Rep, 2002, 22(2): 129-150.
40.	Kshirsagar NA, Pandya SK, Kirodian BG, et al. Liposomal drug delivery system from laboratory to clinic. J Postgrad Med, 2005, 51 Suppl 1: S5-15.
41.	Kim S, Turker MS, Chi EY, et al. Preparation of multivesicular liposomes. Biochim Biophys Acta, 1983, 728(3): 339-348.
42.	Zuidam NJ, Lee SS, Crommelin DJ. Sterilization of liposomes by heat treatment. Pharm Res, 1993, 10(11): 1591-1596.

1. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipid. J Mol Boil, 1965, 13(1): 238-252.
2. Gregoriadis G, Wills EJ, Swain CP, et al. Drug-carrier potential of liposomes in cancer chemotherapy. Lancet, 1974, 1(7870): 1313-1316.
3. 陆彬. 药剂学. 北京: 中国医药科技出版社, 2003: 454.
4. Drulis-Kawa Z, Dorotkiewicz-Jach A. Liposomes as delivery systems for antibiotics. Int J Pharm, 2010, 387(1-2): 187-198.
5. Shen Y, Ji Y, Xu S, et al. Multivesicular liposome formulations for the sustained delivery of ropivacaine hydrochloride: preparation, characterization, and pharmacokinetics. Drug Deliv, 2011, 18(5): 361-366.
6. Cao J, Sun J, Wang X, et al. N-trimethyl chitosan-coated multivesicular liposomes for oxymatrine oral delivery. Drug Dev Ind Pharm, 2009, 35(11): 1339-1347.
7. Akiyama M. Slow change in the repeat period of multilamellar dimyristoyl phosphatidylcholine accompanied by thermal phase transition. Biochim Biophys Acta, 1981, 644(1): 89-95.
8. Bakker-Woudenberg IA. Long-circulating sterically stabilized liposomes as carriers of agents for treatment or for imaging ionfectious foci. Int J Antimicrob Agents, 2002, 19(4): 299-311.
9. Abeylath SC, Turos E. Drug delivery approaches to overcome bacterial resistence to beta-lactam antibiotics. Expert Opin Drug Deliv, 2008, 5(9): 931-949.
10. Jia Y, Joly H, Omri A. Liposomes as a carrier for gentamicin delivery: development and evaluation of the physicochemical properties. Int J Pharm, 2008, 359(1-2): 254-263.
11. Hamidi M, Azadi A, Rafiei P. Pharmacokinetic consequences of pegylattion. Drug Delive, 2006, 13(6): 399-409.
12. Schiffelers R, Storm G, Bakker-Woudenberg I. Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies. J Antimicrob Chemother, 2001, 48(3): 333-344.
13. Bakker-Woudenberg IA, Schiffelers RM, Storm G, et al. Long-circulating sterically stabilized liposomes in the treatment of infections. Methods Enzymol, 2005, 391: 228-260.
14. Beaulac C, Clement-Major S, Hawari J, et al. In vitro kinetics of drug release and pulmonary retention of microencapsulated antibiotic in liposomal formulations in relation to the lipid composition. J Microencapsul, 1997, 14(3): 335-348.
15. Ceh B, Winterhalter M, Frederik PM, et al. Stealth liposomes: from theory to product. Adv Drug Deliv Rev, 1997, 24(2): 165-177.
16. Bakker-Woudenberg IA, ten Kate MT, Guo L, et al. Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection. Antimicrob Agents Chemother, 2002, 46(8): 2575-2581.
17. Bakker-Woudenberg IA, ten Kate MT, Guo L, et al. Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats. Antimicrob Agents Chemother, 2011, 45(5): 1487-1492.
18. Muppidi K, Wang J, Betageri G, et al. PEGylated liposome encapsulation increases the lung tissue concentration of vancomycin. Antimicrob Agents Chemother, 2011, 55(10): 4537-4542.
19. Tomioka H, Saito H, Sato K, et al. Therapeutic efficacy of liposome-encapsulated kanamycin against Mycobacterium intracellulare infection induced in mice. Am Rev Respir Dis, 1991, 144(3 Pt 1): 575-579.
20. Bakker-Woudenberg IA, Lokerse AF, Vink-van den Berg JC, et al. Liposome-encapsulated ampicillin against Listeria monocytogenes in vivo and in vitro. Infection, 1988, 16 Suppl 2: S165-170.
21. Düzgüneş N, Perumal VK, Kesavalu L, et al. Enhanced effect of liposome-encapsulated amikacin on Mycobacterium avium-M. intracellulare complex infection in beige mice. Antimicrob Agents Chemother, 1988, 32(9): 1404-1411.
22. Anderson JC, Kirby CJ. The effect of incorporation of cloxacillin in liposomes on treatment of experimental staphylococcal mastitis in mice. J Vet Pharmacol Ther, 1986, 9(3): 303-309.
23. Bakker-Woudenberg IA, Lokerse AF, Vink-van den Berg JC, et al. Effect of liposome-entrapped ampicillin on survival of Listeria monocytogenes in murine peritoneal macrophages. Antimicrob Agents Chemother, 1986, 30(2): 295-300.
24. Salem II, Düzgüneş N. Efficacies of cyclodextrin-complexed and liposome-encapsulated clarithromycin against Mycobacterium avium complex infection in human macrophages. Int J Pharm, 2003, 250(2): 403-414.
25. Onyeji CO, Nightingale CH, Tessier PR, et al. Activities of clarithromycin, azithromycin, and ofloxacin in combination with liposomal or unencapsulated granulocyte-macrophage colony-stimulating factor against intramacrophage Mycobacterium avium-Mycobacterium intracellulare. J Infect Dis, 1995, 172(3): 810-816.
26. Sou K, Goins B, Oyajobi BO, et al. Bone marrow-targeted liposomal carriers. Expert Opin Drug Deliv, 2011, 8(3): 317-328.
27. Sutherland IW. The biofilm matrix—an immobilised but dynamic environment. Trends Microbiol, 2001, 9(5): 222-227.
28. Kim JH, Gias M, Jones MN. The adsorption of cationic liposomes to Staphylococcus aureus biofilms. Colloids Surf A Physicochem Eng Asp, 1999, 149(1): 561-570．.
29. Tollemar J, Duraj F, Ericzon BG. Liposomal amphotericin B treatment in a 9-month-old liver recipient. Mycoses, 1990, 33(5): 251-252.
30. Katz NM, Pierce PF, Anzeck RA, et al. Liposomal amphotericin B for treatment of pulmonary aspergillosis in a heart transplant patient. J Heart Transplant, 1990, 9(1): 14-17.
31. Halwani M, Yebio B, Suntres ZE, et al. Co-encapsulation of gallium with gentamicin in liposomes enhances antimicrobial activity of gentamicin against Pseudomonas aeruginosa. J Antimicrob Chemother, 2008, 62(6): 1291-1297.
32. Offner F, Krcmery V, Boogaerts M, et al. Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B. Antimicrob Agents Chemother, 2004, 48(12): 4808-4812.
33. Abdel-Rhaman MS, Soliman W, Habib F, et al. A New long-acting liposomal topical antifungal formula: human clinical study. Cornea, 2012, 31(2): 126-129.
34. Okusanya OO, Bhavnani SM, Hammel J, et al. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob Agents Chemother, 2009, 53(9): 3847-3854.
35. 殷凯生, 王彤, 廖万清, 等. 国产注射用两性霉素B脂质体治疗深部真菌病的疗效与安全性的临床研究. 中华医学感染学杂志, 2004, 14(8): 850-854.
36. Sharma A, Sharma US. Liposomes in drug delivery: progress and limitations. Int J Pharm, 1997, 154(2): 123-140.
37. Mouritsen OG, Jørgensen K. A new look at lipid-membrane structure in relation to drug research. Pharm Res, 1998, 15(10): 1507-1519.
38. Gubernator J, Drulis-Kawa Z, Dorotkiewicz-Jach A, et al. In vitro antimicrobial activity of liposomes containing ciprofloxacin, meropenem and gentamicin against Gram-negative clinical bacterial strains. Lett Drug Des Discov, 2007, 4(4): 297-304.
39. Ulrich AS. Biophysical aspects of using liposomes as delivery vehicles. Biosci Rep, 2002, 22(2): 129-150.
40. Kshirsagar NA, Pandya SK, Kirodian BG, et al. Liposomal drug delivery system from laboratory to clinic. J Postgrad Med, 2005, 51 Suppl 1: S5-15.
41. Kim S, Turker MS, Chi EY, et al. Preparation of multivesicular liposomes. Biochim Biophys Acta, 1983, 728(3): 339-348.
42. Zuidam NJ, Lee SS, Crommelin DJ. Sterilization of liposomes by heat treatment. Pharm Res, 1993, 10(11): 1591-1596.

Chinese Journal of Reparative and Reconstructive Surgery

PROGRESS OF LIPOSOMES AS ANTIBIOTIC CARRIERS

Abstract Full text Figures/Tables Video References Cited by

Format

Content